# To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC.

> **NCT02249650** · PHASE1 · COMPLETED · sponsor: **Taiwan Sunpan Biotechnology Development Co., Ltd.** · enrollment: 21 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** TSB-9-W1

## Key facts

- **NCT ID:** NCT02249650
- **Lead sponsor:** Taiwan Sunpan Biotechnology Development Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-10
- **Primary completion:** 2020-02-12
- **Final completion:** 2020-08-25
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2022-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02249650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02249650, "To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02249650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*